With in­vest­ment from Al­loy, Boston pep­tide man­u­fac­tur­er an­nounces Se­ries A

In an ide­al sce­nario, Mytide Ther­a­peu­tics co-founder Dale Thomas pic­tures his com­pa­ny’s tech in hos­pi­tals across Amer­i­ca. On Tues­day, the com­pa­ny an­nounced a $7 mil­lion Se­ries A fundrais­ing round that will help bring that goal a step clos­er to re­al­i­ty.

Mytide will use the mon­ey to ad­vance its Gen2 plat­form, a portable pep­tide man­u­fac­tur­er that it says has the abil­i­ty to pro­duce nat­ur­al and non-nat­ur­al pep­tides about 30 times faster than the tra­di­tion­al man­u­fac­tur­ing process. Thanks to its da­ta col­lec­tion process, Gen2 can help elim­i­nate bot­tle­necks in the sup­ply chain, which have be­come ever-present in the past two years amid the Covid-19 pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER